ActRIIB Variants Treat Neuromuscular, Osteogenesis Imperfecta
Summary
The USPTO published patent application US20260108585A1 on April 23, 2026, covering pharmaceutical compositions of extracellular ActRIIB variant polypeptides fused to Fc domains for treating multiple conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and metabolic disease. The application, filed September 17, 2025, under application number 19331002, names Jasbir S. Seehra, Jennifer Lachey, and Elissa Furutani as inventors. CPC classifications include A61K 38/179, A61K 35/19, and C07K 14/78.
“The invention features polypeptides that include an extracellular ActRIIB variant.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published patent application US20260108585A1 disclosing compositions and methods of use for extracellular ActRIIB variant polypeptides, optionally fused to an Fc domain monomer or moiety, for therapeutic applications. The filing covers treatment of neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and metabolic disease. The application was filed on September 17, 2025, under application number 19331002.
Pharmaceutical companies and researchers developing ActRIIB-related therapeutics should review this published application to assess potential freedom-to-operate considerations and competitive patent landscape. The published CPC codes A61K and C07K indicate the application's relevance to pharmaceutical composition and protein therapeutic development programs.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS OF USING ACTIVIN RECEPTOR TYPE IIB VARIANTS
Application US20260108585A1 Kind: A1 Apr 23, 2026
Inventors
Jasbir S. SEEHRA, Jennifer LACHEY, Elissa FURUTANI
Abstract
The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and metabolic disease.
CPC Classifications
A61K 38/179 A61K 35/19 C07K 14/78 C07K 2319/30
Filing Date
2025-09-17
Application No.
19331002
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.